Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment

Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment

Thu, July 30, 2026 at 4:21 PM GMT+3 3 min read

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for "Meridian Small Cap Growth Fund". A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and healthcare, led the charge, supported by AI-related investments from hyperscalers that added momentum. Meanwhile, traditional safe havens like gold declined. In this context, the Meridian Small Cap Growth Fund (the "Fund") achieved a 21.54% return for the quarter ending June 30, 2026. This lagged behind its benchmark, the Russell 2000 Growth Index, which gained 25.71%, due to factor and style headwinds—as high-beta and momentum stocks soared, its lower-volatility, quality-focused holdings underperformed. The Fund continues to prioritize quality businesses, risk management, and downside protection, with portfolio adjustments driven by strategic allocation rather than weaknesses in individual holdings. In addition, please check the Fund's top five holdings to know its best picks in 2026.

In its Q2 2026 investor letter, Meridian Small Cap Growth Fund highlighted Definium Therapeutics, Inc. (NASDAQ:DFTX). Definium Therapeutics, Inc. (NASDAQ:DFTX), a clinical biopharmaceutical company, contributed to the Fund's performance during the quarter. On July 29, 2026, Definium Therapeutics, Inc. (NASDAQ:DFTX) closed at $42.16 per share, reflecting a market capitalization of $5.6 billion. Definium Therapeutics, Inc. (NASDAQ:DFTX) posted a one-month return of -4.59%, while its shares gained 363.81% over the past 52 weeks.

Meridian Small Cap Growth Fund stated the following regarding Definium Therapeutics, Inc. (NASDAQ:DFTX) in its Q2 2026 investor update:

"Definium Therapeutics, Inc. (NASDAQ:DFTX) is a clinical-stage biopharmaceutical company developing a rapid-acting, single dose LSD-based therapy for major depressive disorder and generalized anxiety disorder, administered in a monitored clinical setting. We own it for its potentially best-in-class profile in large, underserved mental-health markets and a pipeline approaching several pivotal readouts. Shares more than doubled during the quarter after the company reported positive topline results from its pivotal Phase 3 study in major depressive disorder, which comfortably exceeded the efficacy bar investors had set and showed a durable treatment effect with high remission rates versus placebo. The readout meaningfully de-risked the program and set up the first generalized-anxiety-disorder readout, expected shortly, as the next potential catalyst."

Definium Therapeutics, Inc. (NASDAQ:DFTX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 46 hedge fund portfolios held Definium Therapeutics, Inc. (NASDAQ:DFTX) at the end of the first quarter, up from 34 in the previous quarter. While we acknowledge the potential of Definium Therapeutics, Inc. (NASDAQ:DFTX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

In another article, we covered Definium Therapeutics, Inc. (NASDAQ:DFTX) and shared the list of best psychedelic stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. This article is originally published at Insider Monkey.